Anti-resorptive agents reduce the size of resorption cavities: a three-dimensional dynamic bone histomorphometry study.
Anti-resorptive agents reduce the size of resorption cavities: a three-dimensional dynamic bone histomorphometry study.
复制标题
抗吸收剂减少吸收腔的大小：三维动态骨组织形态计量学研究。
DOI：
10.1016/j.bone.2013.08.018
复制
发表时间：
2013
期刊：
影响因子：
4.1
通讯作者：
Hernandez,CJ
中科院分区：
文献类型：
--
作者：
Matheny,JB;Slyfield,CR;Tkachenko,EV;Lin,I;Ehlert,KM;Tomlinson,RE;Wilson,DL;Hernandez,CJ
抗吸收治疗期间吸收腔的改变和骨重建事件被认为有助于降低骨折风险。在这里，我们研究了与选择性雌激素受体调节剂（雷洛昔芬）或双膦酸盐（利塞膦酸盐）治疗相关的个体重塑事件的大小变化。成年雌性大鼠（6月龄）进行卵巢切除术（n = 17）或假手术（SHAM，n = 5）。手术后一个月，卵巢切除动物被分成三组：未处理组（OVX，n = 5）、雷洛昔芬处理组（OVX + Ral，n = 6）和利塞膦酸盐处理组（OVX + Ris，n = 6）。在10个月大时，腰椎进行三维动态骨组织形态测定，以检查个体吸收腔和形成事件的大小（深度、宽度和体积）。最大吸收腔深度在SHAM（23.66 ± 1.87 μm，平均值± SD）和OVX（22.88 ± 3.69 μm）组之间没有差异，但在OVX + Ral（14.96 ± 2.30 μm）和OVX + Ris（14.94 ± 2.70 μm）组中较小（p < 0.01）。抗再吸收治疗与再吸收腔表面积和每个再吸收腔所占体积的减少相关（p < 0.01）。与其他组相比，OVX + Ris组中单个形成事件（双标记事件）的表面积和体积减少（p < 0.02）。与假手术对照组相比，雷洛昔芬治疗组动物显示出相似量的骨重建（ES/BS和dLS/BS），但空腔尺寸（深度、宽度和体积）较小。目前的研究表明，抗再吸收剂影响再吸收腔的大小和个体重塑事件，抗再吸收剂对个体重塑事件的影响可能并不总是与骨重塑的抑制程度直接相关。
Alterations in resorption cavities and bone remodeling events during anti-resorptive treatment are believed to contribute to reductions in fracture risk. Here, we examine changes in the size of individual remodeling events associated with treatment with a selective estrogen receptor modulator (raloxifene) or a bisphosphonate (risedronate). Adult female rats (6 months of age) were submitted to ovariectomy (n = 17) or sham surgery (SHAM, n = 5). One month after surgery, the ovariectomized animals were separated into three groups: untreated (OVX, n = 5), raloxifene treated (OVX + Ral, n = 6) and risedronate treated (OVX + Ris, n = 6). At 10 months of age, the lumbar vertebrae were submitted to three-dimensional dynamic bone histomorphometry to examine the size (depth, breadth and volume) of individual resorption cavities and formation events. Maximum resorption cavity depth did not differ between the SHAM (23.66 ± 1.87 μm, mean ± SD) and OVX (22.88 ± 3.69 μm) groups but was smaller in the OVX + Ral (14.96 ± 2.30 μm) and OVX + Ris (14.94 ± 2.70 μm) groups (p < 0.01). Anti-resorptive treatment was associated with reductions in the surface area of resorption cavities and the volume occupied by each resorption cavity (p < 0.01 each). The surface area and volume of individual formation events (double-labeled events) in the OVX + Ris group were reduced as compared to other groups (p < 0.02). Raloxifene treated animals showed similar amounts of bone remodeling (ES/BS and dLS/BS) compared to sham-operated controls but smaller cavity size (depth, breadth and volume). The current study shows that anti-resorptive agents influence the size of resorption cavities and individual remodeling events and that the effect of anti-resorptives on individual remodeling events may not always be directly related to the degree of suppression of bone remodeling.